microdosing semaglutide menopause Tirzepatide vs for GLP-1 Microdosing for Perimenopause and

Keep the vial in its original box if one was provided, or store it in an opaque bag or container within the refrigerator

In a glycemic control trial evaluating a dose comparable to the 9 mg dose and the 25 mg semaglutide tablet doses in patients with T2D, 1.3% and 1.9% of patients in the 9 mg and 25 mg semaglutide group, respectively, reported moderate-severe non-proliferative diabetic retinopathy events, and 0% and 0.4% reported proliferative retinopathy events, respectively

This precision is one of the strongest arguments for vial-based dosing, especially during the critical early phases when finding your personal tolerance threshold matters most

Ozempic European Medicines Agency EPAR

Do not try to "catch up" by injecting more

doi: 10.2337/dc16-2684 68 SteinbergWMBuseJBGhorbaniMLMrstedDDNauckMALEADER Steering Committeeet al